Literature DB >> 6694049

Picolinic acid in acrodermatitis enteropathica: evidence for a disorder of tryptophan metabolism.

I Krieger, R Cash, G W Evans.   

Abstract

Three children with acrodermatitis enteropathica (AE) were treated with oral zinc dipicolinate (zinc-PA). The daily dose of zinc required to prevent exacerbations, when administered as the dipicolinate complex, was one-third the minimum amount of zinc required as the sulfate salt. The concentration of picolinic acid in the plasma of asymptomatic children with AE was significantly less than that of normal children. However, oral treatment with PA alone was ineffective. The plasma of the three AE children contained a measurable quantity of kynurenine which was undetectable in plasma from normal children. Absorption of an oral zinc load was normal. The results support the hypothesis that the genetic defect in AE is in the tryptophan pathway, although the role of PA in zinc metabolism remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6694049     DOI: 10.1097/00005176-198401000-00014

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  4 in total

1.  The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects.

Authors:  R I Press; J Geller; G W Evans
Journal:  West J Med       Date:  1990-01

2.  The effect of the acrodermatitis enteropathica mutation on zinc uptake in human fibroblasts.

Authors:  F Vazquez; A Grider
Journal:  Biol Trace Elem Res       Date:  1995-11       Impact factor: 3.738

Review 3.  Clinical and laboratory diagnosis of acrodermatitis enteropathica.

Authors:  J P Van Wouwe
Journal:  Eur J Pediatr       Date:  1989-10       Impact factor: 3.183

Review 4.  A review on α-glucosidase inhibitory activity of first row transition metal complexes: a futuristic strategy for treatment of type 2 diabetes.

Authors:  Marzieh Sohrabi; Mohammad Reza Binaeizadeh; Aida Iraji; Bagher Larijani; Mina Saeedi; Mohammad Mahdavi
Journal:  RSC Adv       Date:  2022-04-20       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.